Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Income from Continuing Operations (2022 - 2025)

Entrada Therapeutics has reported Income from Continuing Operations over the past 4 years, most recently at 39140000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 39140000.0 for Q4 2025, down 3737.55% from a year ago — trailing twelve months through Dec 2025 was 143794000.0 (down 319.16% YoY), and the annual figure for FY2025 was 143726000.0, down 319.09%.
  • Income from Continuing Operations for Q4 2025 was 39140000.0 at Entrada Therapeutics, up from 44180000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TRDA hit a ceiling of 55031000.0 in Q2 2024 and a floor of 44180000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 4 years was 19510000.0 (2022), compared with a mean of 11214812.5.
  • Biggest five-year swings in Income from Continuing Operations: soared 452.05% in 2024 and later crashed 3737.55% in 2025.
  • Entrada Therapeutics' Income from Continuing Operations stood at 24629000.0 in 2022, then skyrocketed by 61.25% to 9544000.0 in 2023, then soared by 111.27% to 1076000.0 in 2024, then crashed by 3737.55% to 39140000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 39140000.0 (Q4 2025), 44180000.0 (Q3 2025), and 43125000.0 (Q2 2025) per Business Quant data.